Translating Haematology’s Successes: Leveraging Immune Costimulation Lessons to Advance Solid Tumor Therapies
- Establishing the clinical PoM for two distinct costimulators, Englumafusp alfa (4-1BB) and CD28, in combination with Glofitamab for r/r NHL, showing how each engages a unique immunologic pathway
- Presents biomarker evidence (e.g., peripheral memory T‑cell expansion, ctDNA reduction) linking 4‑1BB to durable, late responses and CD28 to rapid, early tumor killing
- Identifies tumor microenvironment profiles where each costimulatory pathway performs optimally, supporting more personalized treatment selection for poor‑prognosis patients